April 6, 2015 — The family of a boy who was born with birth defects after his mother used Zofran during pregnancy has filed a lawsuit against GlaxoSmithKline (GSK) in federal court in Alabama.
The boy’s mother was prescribed Zofran to treat nausea during the first trimester of pregnancy. Eight months later, she gave birth to a boy with a chromosomal defect that caused a wide range of birth defects.
According to the lawsuit (PDF), these birth defects include:
- Distended kidney and ureteral disorder
- High narrow pallet
- Seizure disorder
- Extra digits on his hands
- Non-verbal and delayed reactions
Genetic testing on the boy’s parents found no evidence of hereditary chromosomal conditions that could be passed to the boy congenitally. The lawsuit blames Zofran for his injuries. It also accuses GSK of negligence for failing to warn that Zofran is “defective and unreasonably dangerous.”
Numerous studies published in the last few years have shown that Zofran passes through the placenta and increases the risk of cleft palate, heart defects, and birth defects. Even so, GSK has not updated the warning label on Zofran or conducted studies to fully investigate the risk.
Every year, about 1 million pregnant women are prescribed Zofran “off-label” for the treatment of morning sickness. Many of these women do not realize that Zofran is not approved or recommended for use during pregnancy.
Do I have a Zofran Lawsuit?
The Schmidt Firm, PLLC is currently accepting Zofran induced injury cases in all 50 states. If you or a loved one had a baby with a birth defect, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Drug Litigation Group or call toll free 24 hours a day at (866) 920-0753.
Attention Lawyers: We consider a referral from another law firm to be one of the greatest compliments. If your firm is interested in referring us a case or for us to send you a list of previous award judgments and/or average referral fees, please visit the Lawyer Referral section of our website.